Upgrade to SI Premium - Free Trial

Alexion (ALXN) Buy On Weakness - Piper Jaffray

June 7, 2016 9:29 AM
Piper Jaffray analyst, Joshua Schimmer, noted that after the close, Alexion Pharmaceuticals (NASDAQ: ALXN) reported topline results from Phase 3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA

Next Articles